search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants.

Paola Ghione ,
Diana Mandelker ,
Maria Arcila ,
Venkatraman Seshan ,
Mary Beth Terry ,
Joseph Vijai ,
Peter Cordeiro ,
Chad Vanderbilt ,
Joyce Pressley ,
Alexander Chan ,
Natasha Galasso ,
Ahmet Dogan ,
Gilles Salles ,
Daphne de Jong ,
Flora van Leeuwen ,
Steven Horwitz

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a type of T-cell lymphoma arising near textured breast implants. In a Dutch population, a higher prevalence of BRCA1/2 was found in BIA-ALCL. We analyzed the risk of BIA-ALCL occurrence related to BRCA in a large population of women with implants followed after breast cancer (BC) mastectomy. We compared the prevalence of BRCA1/2 between women from a large cohort of patients with BC who did and did not develop BIA-ALCL after reconstruction with textured implants. Hazard ratios (HRs) of developing BIA-ALCL were estimated using Cox regression. We also conducted a case-control study. Of 520 patients with BC tested for BRCA, the age-adjusted rate of developing BIA-ALCL for women with BRCA was 16 times the rate of BIA-ALCL among women without BRCA (95% confidence interval [CI], 3.6-76.1; P < .0003). Carrying bilateral implants (HR, 3.9; 95% CI, 0.4-32.7), chemotherapy (HR, 0.95; 95% CI, 0.2-4.2), and radiotherapy (HR, 0.37; 95% CI, 0.04-3.1) were not associated with BIA-ALCL. We also conducted a case-control study with 13 BIA-ALCL patients matched 1:3 with 39 controls. We used a complete enumeration of Bernoulli probability to rule out a nonassociation of BRCA with BIA-ALCL (P = .0002). In this study, we defined the role of BRCA1/2 mutations as a risk factor in developing BIA-ALCL in patients with BC. These results will help women undergoing breast reconstruction or with textured implants in place.

More about this publication

Blood advances

Volume 9
Issue nr. 17
Pages 4436-4443
Publication date 09-09-2025

Full text links

Publisher website (DOI) 10.1182/bloodadvances.2025016810
Europe PubMed Central 40512039
Pubmed 40512039

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.